GLP-1

Combining PLLA and Skin Boosters for GLP-1 Patients

Dr Catherine Denning considers PLLA with HA skin boosters for weight-loss side effects The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity management has transformed weight-loss outcomes for many patients.¹⁻³ While GLP-1 medication can deliver metabolic benefits, rapid …

To access this post, you must purchase Aesthetics Journal Subscriptions – AJ Print & Digital Subscriber, Aesthetics Journal Subscriptions – AJ Digital Subscriber or Aesthetics Journal Subscriptions – AJ News Subscriber.

IMAGE Skincare debuts VOL.U.LIFT Body

Skincare company IMAGE Skincare has released topical formulation VOL.U.LIFT Body designed for weight-loss side effects. Available through aesthetic distributor Wigmore Medical, the new body formula is designed to address the

New drug aims to combat muscle loss in GLP-1 patients

A new investigational drug called apitegromab is being explored to preserve muscle mass in adults receiving glucagon-like peptide‑1 (GLP‑1) receptor agonists for obesity. The BBC has reported on a Nature Medicine study

Spotting Vulnerable GLP-1 patients

Psychologist Kimberley Cairns proposes a cognitively informed GLP-1 approach for aesthetic practice Glucagon-like peptide-1 (GLP-1) receptor agonists have reshaped discussions around weight, identity and appearance. In UK aesthetic practice, clinicians are increasingly seeing patients whose bodies, and sometimes decision-making, are …

ASA releases research on weight-loss adverts

The Advertising Standards Authority (ASA) has published new research into how patients interpret weight-loss treatment advertisements. The findings show that, out of 2,030 participants, most believe weight-loss treatment advertisements can

Maintaining GLP-1 Weight Loss Through Body Devices

Dr Marwa Ali examines the role of body devices in GLP-1–associated weight loss The use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, has grown rapidly in medical weight management.¹ With patients achieving significant weight loss and …

CPD: Treating Muscle Loss with Devices

Skeletal muscle is a dynamic, metabolically active organ essential for maintaining health throughout the lifespan. Beyond providing strength and locomotion, muscle regulates glucose metabolism, supports immune signalling and contributes to endocrine communication through the secretion of myokines.1 A decline in …

To access this post, you must purchase Aesthetics Journal Subscriptions – AJ Print & Digital Subscriber or Aesthetics Journal Subscriptions – AJ Digital Subscriber.

ASA bans affiliate-linked social media ads for prescription weight-loss drugs

The Advertising Standards Authority (ASA) has banned a series of social media advertisements promoting prescription-only weight-loss medicines (POMs) through affiliate and referral links. The organisation notes that these rulings mark

Managing Post-Weight Loss Skin Changes

Dr Ahmed El Muntasar presents an overview of strategies for addressing post-weight loss skin changes Significant weight loss, whether achieved through lifestyle modification, bariatric surgery or pharmacological interventions such as glucagon-like peptide-1 (GLP-1) receptor agonists, is increasingly common in clinical …

The Private Clinic hosts education event on GLP-1 aftercare

Aesthetics attended a panel discussion at The Private Clinic designed to educate, reassure and reframe the conversation around post-weight-loss care. The expert panel was led by journalist Emma Gunavardhana and featured

Latest news

Fotona appoints CPO

CPD: Understanding Peptides

Phorest unveils speakers for 2027 summit

JCCP issues guidance to maintain compliant advertising

Petition to scrap tax on SPF reaches Parliament

Parliament hears evidence on cosmetic procedures

The Aesthetics Journal | September 2026

XERF launches in the UK

BAD advocates for skincare warnings

Special Feature: Showcasing the Use of Peptides in Skincare